Vitamin D and cardiovascular disease risk: Emerging evidence

Current Opinion in Cardiology

Volumn 25, Issue 5, 2010, Pages 513-517

  Swales, Heather H ^a   Wang, Thomas J ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

blood pressure; cardiovascular disease; diabetes mellitus; metabolic syndrome; supplementation; vitamin D

Indexed keywords

1,25 DIHYDROXY VITAMIN D; CALCIFEDIOL; COLECALCIFEROL; ERGOCALCIFEROL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; HUMAN; INSULIN RESISTANCE; MORTALITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCREENING; SYSTOLIC BLOOD PRESSURE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; CARDIOVASCULAR DISEASES; COMPLICATION; PATHOPHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 77955466842     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833cd491     Document Type: Review

References (66)

1. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-511.
2. Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93:3927-3935.
3. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205:255-260. This large, cross-sectional study provides further evidence that low vitamin D levels are associated with cardiovascular disease, even after accounting for potential confounders.
4. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with allcause and cardiovascular mortality. Arch Intern Med 2008; 168:1340-1349.
5. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008; 168:1174-1180.
6. Orwoll E, Nielson CM, Marshall LM, et al. Vitamin D deficiency in older men. J Clin Endocrinol Metab 2009; 94:1214-1222.
7. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169:626-632.
8. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 Vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97:1577-1588.
9. O'Connell TD, Berry JE, Jarvis AK, et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272:H1751-H1758.
10. Yuan W, Pan W, Kong J, et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282:29821-29830.
11. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
12. Tishkoff DX, Nibbelink KA, Holmberg KH, et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008; 149:558-564.
13. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103:521-524.
14. Zhou C, Lu F, Cao K, et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74:170-179.
15. Giulietti A, van Etten E, Overbergh L, et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77:47-57.
16. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987; 79:1659-1664.
17. Oh J, Weng S, Felton SK, et al. 1,25(OH)2 Vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009; 120:687-698. This study provides further experimental evidence that vitamin D influences lipid metabolism and modulates atherogenesis.
18. Kasuga H, Hosogane N, Matsuoka K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun 2002; 297:1332-1338.
19. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991; 87:1889-1895.
20. Wu-Wong JR, Nakane M, Ma J, et al. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186:20-28.
21. Cardus A, Parisi E, Gallego C, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway.Kidney Int 2006; 69:1377-1384.
22. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha,25-Dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87:214-220.
23. Somjen D, Weisman Y, Kohen F, et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111:1666-1671.
24. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279:35798-35802.
25. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987; 253:E675-E683.
26. Almirall J, Vaqueiro M, Bare ML, Anton E. Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly.Nephrol Dial Transplant 2010; 25:503-509.
27. Schmitz KJ, Skinner HG, Bautista LE, et al. Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 2009; 22:867-870.
28. Scragg RK, Camargo CA Jr, Simpson RU. Relation of serum 25-hydroxyvitamin D to heart rate and cardiac work (from the National Health and Nutrition Examination Surveys). Am J Cardiol 2010; 105:122-128. Based on an analysis of the National Health and Nutrition Survey database, this report explores hemodynamic correlates of vitamin D insufficiency.
29. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49:1063-1069.
30. Kim MK, Kang MI, Oh KW, et al. The association of serum vitamin D level with presence of metabolic syndrome and hypertension in middle-aged Korean subjects. Clin Endocrinol (Oxf) 2010. [Epub ahead of print]
31. Jorde R, Figenschau Y, Emaus N, et al. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 2010; 55:792-798. This Norwegian study confirms the cross-sectional association of low vitamin D levels with elevated BP, but fails to find an association with incident hypertension.
32. Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: The Women's Health Initiative Randomized Trial. Hypertension 2008; 52:847-855.
33. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J Hypertens 2009; 27:1948-1954. This is the first meta-analysis of clinical trials of vitamin D supplementation and BP.
34. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152:307-314. This is a comprehensive review of observational and interventional studies focused on vitamin D and cardiovascular and metabolic endpoints. The findings emphasize the need for further prospective, randomized trials in this area.
35. Lee DM, Rutter MK, O'Neill TW, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol 2009; 161:947-954.
36. Lu L, Pan A, Hu FB, et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009; 32:1278-1283.
37. Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic Adults. J Nutr 2009; 139:329-334.
38. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010; 33:1379-1381.
39. Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010; 33:1373-1375.
40. Kositsawat J, Freeman VL, Gerber BS, Geraci S. Association of A1c levels with vitamin D status in U.S. Adults: Data from the National Health and Nutrition Examination Survey. Diabetes Care 2010; 33:1236-1238.
41. Gulseth HL, Gjelstad IM, Tierney AC, et al. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care 2010; 33:923-925.
42. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient -a randomised, placebo-controlled trial. Br J Nutr 2010; 103:549-555.
43. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009; 26:19-27.
44. Luo C, Wong J, Brown M, et al. Hypovitaminosis D in Chinese type 2 diabetes: Lack of impact on clinical metabolic status and biomarkers of cellular inflammation. Diab Vasc Dis Res 2009; 6:194-199.
45. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 2009; 48:349-354.
46. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic Adults. Diabetes Care 2007; 30:980-986.
47. Rajpathak SN, Xue X, Wassertheil-Smoller S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: Results from the Women's Health Initiative. Am J Clin Nutr 2010; 91:894-899.
48. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89:1321-1327. This moderately sized clinical trial examines the effect of vitamin D supplementation on several metabolic markers.
49. Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D status: The Framingham Heart Study. Diabetes 2010; 59:242-248. This is one of the largest studies relating vitamin D status with detailed measures of fat distribution, obtained via computed tomography. Interestingly, vitamin D status was related to fat deposition, even among lean individuals.
50. Lagunova Z, Porojnicu AC, Lindberg F, et al. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 2009; 29:3713-3720.
51. Young KA, Engelman CD, Langefeld CD, et al. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab 2009; 94:3306-3313.
52. Freedman BI, Wagenknecht LE, Hairston KG, et al. Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 2010; 95:1076-1083.
53. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf) 2009; 71:666-672.
54. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and allcause mortality in older U.S. Adults. J Am Geriatr Soc 2009; 57:1595-1603. This analysis of longitudinal data from the National Health and Nutrition Survey shows robust association of vitamin D status with cardiovascular and all-cause mortality. The report corroborates and extends findings of earlier observational studies.
55. Semba RD, Houston DK, Ferrucci L, et al. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community- dwelling women. Nutr Res 2009; 29:525-530.
56. Szulc P, Claustrat B, Delmas PD. Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men -the MINOS study. Clin Endocrinol (Oxf) 2009; 71:594-602.
57. Kilkkinen A, Knekt P, Aro A, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 2009; 170:1032-1039. This large Finnish study also demonstrates an association of low vitamin D status with cardiovascular death. The findings specifically highlight the association between vitamin D status and cerebrovascular death.
58. Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010; 171:903-908. This study examines the tracking of 25-hydroxy vitamin D levels in a large Norwegian sample. It is one of the few studies to provide longitudinal data for a vitamin D measure, and suggests that intraindividual variability is comparable with that of established cardiovascular risk factors.
59. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317-322.
60. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2009. [Epub ahead of print] This is a systematic review of prior musculoskeletal trials, which attempts to define optimal ranges for vitamin D concentration.
61. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85:6-18.
62. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88:582S-586S.
63. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: Calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997.
64. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
65. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93:677-681.
66. Lee P, Greenfield JR, Seibel MJ, et al. Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med 2009; 122:1056-1060. This study emphasizes the potential importance of adiposity in determining the response to vitamin D supplementation.